Patents by Inventor Peter Ronald Young

Peter Ronald Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20170182029
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: March 15, 2017
    Publication date: June 29, 2017
    Inventors: Shuang LIU, John Frederick QUINN, Bryan Cordell DUFFY, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, He ZHAO, Michael ELLIS, Gregory Steven WAGNER, Peter Ronald YOUNG
  • Bicyclic bromodomain inhibitors
    Patent number: 9663520
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: May 30, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: John Frederick Quinn, Bryan Cordell Duffy, Shuang Liu, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, Gregory Steven Wagner, Peter Ronald Young
  • Substituted bicyclic compounds as bromodomain inhibitors
    Patent number: 9662311
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: May 30, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20170143731
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: February 3, 2017
    Publication date: May 25, 2017
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young
  • Substituted bicyclic compounds as bromodomain inhibitors
    Patent number: 9636328
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: May 2, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • Heterocyclic compounds as bromodomain inhibitors
    Patent number: 9598367
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: March 21, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young
  • NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20160184273
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: June 20, 2014
    Publication date: June 30, 2016
    Applicant: ZENITH EPIGENETICS CORP.
    Inventors: Shuang LIU, John Frederick QUINN, Bryan Cordell DUFFY, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, He ZHAO, Michael ELLIS, Gregory Steven WAGNER, Peter Ronald YOUNG
  • NOVEL BICYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20160159801
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: December 21, 2015
    Publication date: June 9, 2016
    Inventors: John Frederick QUINN, Bryan Cordell DUFFY, Shuang LIU, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, Gregory Steven WAGNER, Peter Ronald YOUNG
  • NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20160145248
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: June 20, 2014
    Publication date: May 26, 2016
    Inventors: Shuang LIU, John Frederick QUINN, Bryan Cordell DUFFY, Ruifang WANG, May Xiacwu JIANG, Gregory Scott MARTIN, He ZHAO, Michael ELLIS, Gregory Steven WAGNER, Peter Ronald YOUNG
  • Novel Heterocyclic Compounds as Bromodomain Inhibitors
    Publication number: 20160130228
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: January 15, 2016
    Publication date: May 12, 2016
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young
  • Cyclic amines as bromodomain inhibitors
    Patent number: 9278940
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: March 8, 2016
    Assignee: Zenith Epigenetics Corp.
    Inventors: David John Fairfax, Bryan Cordell Duffy, Gregory Scott Martin, John Frederick Quinn, Shuang Liu, Gregory Steven Wagner, Peter Ronald Young
  • Heterocyclic compounds as bromodomain inhibitors
    Patent number: 9271978
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 1, 2016
    Assignee: Zenith Epigenetics Corp.
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young
  • CYCLIC AMINES AS BROMODOMAIN INHIBITORS
    Publication number: 20150344442
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: June 3, 2015
    Publication date: December 3, 2015
    Applicant: Zenith Epigenetics Corp.
    Inventors: David John Fairfax, Bryan Cordell Duffy, Gregory Scott Martin, John Frederick Quinn, Shuang Liu, Gregory Steven Wagner, Peter Ronald Young
  • Cyclic amines as bromodomain inhibitors
    Patent number: 9073878
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: July 7, 2015
    Assignee: Zenith Epigenetics Corp.
    Inventors: David John Fairfax, Bryan Cordell Duffy, Gregory Scott Martin, John Frederick Quinn, Shuang Liu, Gregory Steven Wagner, Peter Ronald Young
  • Novel Heterocyclic Compounds as Bromodomain Inhibitors
    Publication number: 20140179648
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: December 19, 2013
    Publication date: June 26, 2014
    Applicant: RVX Therapeutics Inc.
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young
  • BIARYL DERIVATIVES AS BROMODOMAIN INHIBITORS
    Publication number: 20140140956
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: November 20, 2013
    Publication date: May 22, 2014
    Applicant: RVX Therapeutics Inc.
    Inventors: David John Fairfax, Gregory Scott Martin, John Frederick Quinn, Bryan Cordell Duffy, Gregory Steven Wagner, Peter Ronald Young
  • CYCLIC AMINES AS BROMODOMAIN INHIBITORS
    Publication number: 20140142102
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: November 20, 2013
    Publication date: May 22, 2014
    Applicant: RVX Therapeutics Inc.
    Inventors: David John Fairfax, Bryan Cordell Duffy, Gregory Scott Martin, John Frederick Quinn, Shuang Liu, Gregory Steven Wagner, Peter Ronald Young
  • TREATMENT OF DISEASES BY EPIGENETIC REGULATION
    Publication number: 20130281397
    Abstract: The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 24, 2013
    Applicant: RVX Therapeutics Inc.
    Inventors: Kevin G. McLure, Peter Ronald Young
  • Novel compounds
    Publication number: 20030064481
    Abstract: A soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity comprises an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.
    Type: Application
    Filed: January 16, 2002
    Publication date: April 3, 2003
    Applicant: SmithKline Beecham Corporation and SmithKline Beecham p.l.c.
    Inventors: Michael Joseph Browne, Peter Ronald Young, Allan Richard Shatzman, Kay Elizabeth Murphy, Conrad Gerald Chapman, Helen Elizabeth Clinkenbeard
  • Interleukin-1 receptor antagonist beta (IL-1rabeta)
    Patent number: 6399573
    Abstract: IL-1ra beta polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing IL-1ra beta polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, septicemia, arthritis, inflammatory bowel disease, graft vs. host disease, autoimmunity, stroke, cardiac ischemia, acute respiratory disease syndrome (ARDS), psoriasis, restenosis, traumatic brain injury, AIDS, cachexia, allergy, parasite infection, allergic rhinitis, allergic asthma, atopic dermatitis, allergic inflammatory diseases, and delayed hypersensitivity, among others, and diagnostic assays for such conditions.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: June 4, 2002
    Assignee: SmithKline Beecham Corporation
    Inventor: Peter Ronald Young